TIDMNCYT
Novacyt S.A.
28 July 2022
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Launch of research-use-only a denovirus F41 assay
The assay has been developed by Novacyt to support research
efforts following a recent increase in cases of acute hepatitis in
children
Paris, France and Camberley, UK - 28 July 2022 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces the launch of a research-use-only
(RUO) polymerase chain reaction (PCR) assay for the detection of
adenovirus F41, in response to recent cases of acute hepatitis in
children. This launch expands Novacyt's genesig(R) real-time PCR
diagnostic product portfolio and is in line with the Company's
strategy to maintain its position as a global first responder in
infectious diseases.
Adenoviruses are a large group of viruses divided into several
species and subtypes. They are the cause of several illnesses,
usually exhibiting as colds or flu-like illness, which may also
cause gastrointestinal symptoms such as diarrhoea. Adenoviruses are
primarily spread via respiratory droplets; however, they can also
be spread by faecal routes. Ongoing investigations, particularly in
the UK, have identified adenovirus infection in children, and in
particular, adenovirus F41 in several cases.
This assay has been developed in two forms, genesig(R) Advanced
and genesig(R) Easy, designed for in vitro detection of adenovirus
species F serotype 41 genomes, without detecting any closely
related adenovirus sequences. Novacyt's genesig(R) Advanced assay
is configured for use with any open test platform, including
Novacyt's MyGo instruments, the genesig(R) Easy assay is suitable
for use on the Company's q16 and q32 instruments.
Novacyt, through its specialist bioinformatics surveillance
expertise, continually tracks the changing pathology of diseases
worldwide, and will regularly review the detection profile of
assays, ensuring that new versions are developed if necessary.
David Allmond, Chief Executive Officer of Novacyt,
commented:
"Our RUO adenovirus F41 assay has been developed in response to
recent cases of acute hepatitis in children to support research
efforts in determining the cause of this severe disease. The launch
of this new assay, as well as our recent assay for the detection of
the Monkeypox virus, subsequently declared a global health
emergency by the WHO, reinforce Novacyt's position as a global
first responder, as well as our commitment to expanding our
portfolio in infectious diseases, both in line with our stated
strategy. Our extensive leading RUO portfolio consists of over 850
products, spanning veterinary, food, environment, and human health
research. The portfolio is a key part of our core business and
serves as an innovation engine for the Company as we transition
beyond the Covid-19 pandemic."
- End -
Contacts
Novacyt SA
David Allmond, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com / Novacyt.group@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company supplies an extensive range of high-quality assays and
reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates
For more information, please refer to the website:
www.novacyt.co m
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRARRMBTMTMTTLT
(END) Dow Jones Newswires
July 28, 2022 02:00 ET (06:00 GMT)
Novacyt (EU:ALNOV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Novacyt (EU:ALNOV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
